AstraZeneca Receives Final Regulatory Clearance for $39 Billion Acquisition of Alexion Pharmaceuticals
AstraZeneca
Biopharmaceutical Manufacturer
Alexion
Developer of New Drugs for Rare Disease Treatment
Competition and Markets Authority
The Competition and Markets Authority (CMA) is a non-ministerial department in the United Kingdom. It was launched in shadow form on October 1, 2013, and became fully operational on April 1, 2014, with the responsibility of strengthening business competition and preventing and reducing anti-competitive activities.
On July 14, AstraZeneca announced that the UK Competition and Markets Authority (CMA) has approved its acquisition of Alexion Pharmaceuticals ("Alexion"). Consequently, the acquisition is expected to close on July 21, 2021. Upon completion of the acquisition, a group focused on rare diseases will be established. This group will be named "Alexion, AstraZeneca Rare Disease" and will be headquartered in Boston, USA.
*Disclaimer: This article was authored by a contributing writer to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.